Management of Atrial Flutter
Catheter ablation is the first-line treatment for atrial flutter, with success rates exceeding 90%, and should be pursued rather than long-term antiarrhythmic drug therapy 1, 2.
Anticoagulation Strategy
Treat atrial flutter identically to atrial fibrillation for thromboembolism risk:
Use CHA2DS2-VA score to guide anticoagulation decisions 3:
- Score ≥2: Anticoagulation recommended
- Score = 1: Anticoagulation should be considered
- Score = 0: Low risk, anticoagulation generally not needed
DOACs (apixaban, dabigatran, edoxaban, rivaroxaban) are preferred over warfarin, except in mechanical heart valves or mitral stenosis 3
Continue anticoagulation regardless of rhythm status—even after successful ablation or cardioversion, base the decision on stroke risk, not whether the patient is currently in sinus rhythm 3
Cardioversion-Specific Anticoagulation
- If flutter duration <48 hours and low stroke risk: Can cardiovert without prior anticoagulation 4
- If flutter duration ≥48 hours or unknown duration: Provide at least 3 weeks of anticoagulation before cardioversion, then continue for ≥4 weeks after 4
- High-risk patients (mechanical valve, recent stroke/TIA): Give heparin before or immediately after cardioversion regardless of duration 4
Acute Management Algorithm
Hemodynamically Unstable Patients
- Immediate synchronized electrical cardioversion 4
- Administer heparin before cardioversion if possible, or immediately after if delay is unacceptable 4
Stable Patients
You have two equally valid initial approaches 4:
Rate Control Option:
- Beta-blockers (any ejection fraction)
- Digoxin (any ejection fraction)
- Diltiazem or verapamil (only if LVEF >40%) 3
Rhythm Control Option:
- Electrical or pharmacological cardioversion based on patient preference and characteristics 3
- Requires appropriate anticoagulation as outlined above
Definitive Long-Term Management
Catheter ablation is the gold standard for atrial flutter 1, 2:
- Success rate >90% for typical atrial flutter 5, 1
- Creates scar tissue across the cavo-tricuspid isthmus to eliminate the reentrant circuit 1
- Should be considered first-line rather than waiting for antiarrhythmic drug failure 2
Important Caveat
Atrial fibrillation frequently develops after successful flutter ablation 1—patients need continued monitoring and may require additional management for AF.
When Antiarrhythmic Drugs Are Used
If ablation is refused, unavailable, or contraindicated, antiarrhythmic drugs are second-line 6, 7. However, atrial flutter is notoriously resistant to pharmacotherapy 1, making this a suboptimal long-term strategy.
Key Clinical Pitfalls
- Do not use antiplatelet therapy as substitute for anticoagulation—avoid combining unless acute vascular event or procedural need 3
- Do not stop anticoagulation after successful cardioversion or ablation if stroke risk remains elevated 3
- Rate control with calcium channel blockers or digoxin alone may be inadequate for flutter due to the organized atrial activity—ventricular rates can suddenly conduct 1:1, causing hemodynamic collapse
- Recognize that flutter and fibrillation frequently coexist—manage with the assumption that both may be present 5, 8